B-Cell Malignancies Clinical Trials

A listing of B-Cell Malignancies medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 83 clinical trials
Featured trial
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.

  • 0 views
  • 22 Oct, 2022
  • 20 locations
Featured trial
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lymphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)

Background: The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these methods in a natural history study can clarify …

marginal zone lymphoma
lymphadenopathy
cancer
lymphocytosis
chronic lymphocytic leukemia
  • 115 views
  • 15 Apr, 2019
  • 1 location
Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.

  • 0 views
  • 23 Mar, 2022
  • 2 locations
  • 4 views
  • 27 Jan, 2021
  • 1 location
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

inhibitor, for the treatment of adult patients with B-cell malignancies.

  • 0 views
  • 19 Jun, 2022
  • 1 location
This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

This is a Phase 1 study of MH048 in patients with selected Relapsed/Refractory B-cell Malignancies.

  • 0 views
  • 15 Sep, 2021
  • 1 location
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).

  • 0 views
  • 11 Nov, 2021
  • 1 location
Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART22 (Allogeneic CAR-T targeting CD22) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).

  • 0 views
  • 17 Nov, 2021
  • 1 location
CD19/79b Bi-specific CAR-T Cell Therapy

The purpose of this study is to assess the feasibility, safety and efficacy of CD19/79b bi-specific CAR-T cell therapy in patients with CD19 and/or CD79b positive B cell malignancies. Another

  • 0 views
  • 07 Jul, 2022
  • 1 location
CD19/22 Bi-specific CAR-T Cell Therapy

The purpose of this study is to assess the feasibility, safety and efficacy of anti-CD19/22 bi-specific CAR-T cell therapy in patients with CD19 and/or CD22 positive B cell malignancies. Another

  • 0 views
  • 07 Jul, 2022
  • 1 location